VivoSeq
Other

Brentuximab Vedotin

0

Pipeline Programs↗

5

Active Trials↗

1

Companies Involved↗

Brentuximab Vedotin is an early-stage landscape with 0 programs across 1 company. The most active players are Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

57/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

21

clinical trials

Completed8 · 38%
Recruiting4 · 19%
Withdrawn3 · 14%
Terminated3 · 14%
Unknown status1 · 5%
Not yet recruiting1 · 5%
Other1 · 5%

Clinical Trials

Trial Activity

21 trials

Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT05149768·11 enrolled
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
Recruiting·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT04378647·150 enrolled
Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
Recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT07074457·47 enrolled
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Recruiting·CChildren's Cancer Group, China·Phase 2/3·NCT06563245·96 enrolled
Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06925555·25 enrolled
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine
Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT03496779·71 enrolled
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02298283·40 enrolled
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Completed·Pfizer logoPfizer·Phase 2·NCT00947856·110 enrolled
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
Completed·Pfizer logoPfizer·Phase 1·NCT01309789·39 enrolled
BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV
Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02244021·13 enrolled
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
Completed·Pfizer logoPfizer·Phase 1·NCT01026233·52 enrolled
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Completed·Pfizer logoPfizer·Phase 2·NCT04569032·82 enrolled
Brentuximab Vedotin for Steroid Refractory GvHD
Completed·MMassachusetts General Hospital·Phase 1·NCT01596218·35 enrolled
Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus
Terminated·Pfizer logoPfizer·Phase 2·NCT02533570·20 enrolled
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting
Terminated·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02499627·43 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)